U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C4H5N4O3.2Al.Cl.4HO
Molecular Weight 314.553
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALCLOXA

SMILES

[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)[N-]C1=O

InChI

InChIKey=IMZDRXBSGZPLDE-UHFFFAOYSA-H
InChI=1S/C4H6N4O3.2Al.ClH.4H2O/c5-3(10)6-1-2(9)8-4(11)7-1;;;;;;;/h1H,(H5,5,6,7,8,9,10,11);;;1H;4*1H2/q;2*+3;;;;;/p-6

HIDE SMILES / InChI
The aluminum salt of Allantoin, Alcloxa combines the astringent and anti-microbial properties of aluminum with the anti-irritant, soothing and healing properties of Allantoin. Alcloxa is particularly suited for use in anti-perspirants, acne treatments and foot care products. Alcloxa is a compound that combine the properties of aluminum salts with the properties of allantion. The allantion component ehhances the action of the aluminum salts and serves to overcome irritations experienced by many individuals who may be sensitive to the use of aluminum alts. The aluminum component reduces sweat by causing the sweat gland ducts swell. Alcloxa also add to the antiperspirant properties the deodorant effect because of its bacteriostatic action. It showed bacteriostatic properties at concentrations of 0.2% particularly against Gram bectaria (B. subtilis, S. aureus, P. vulgaris, Pityrosporum ovale). This is ascribable to two different mechanisms: first bacterial growth is retarded due to a decrease in the amount of water present, second aluminum salt have itself an antimicrobial action. In baby products is indicated for its healing reparative action, in the treatment of diaper rash. Also is approved in haemorrhoidal product for its soothing and keratolytic action. In oral care products Alcloxa is useful for its astringent antibacterial properties. It is very indicated in formulations for sensitive teeth, periodontal and gum diseases (like gingivitis, irritable and bleeding gums). Use levels: 0.1-1%. − In antiacne products the slightly astringent effect promotes healing of pustules and acne lesions. It reduces the extension of infected skin eruptions, healing them and developing a soothing action. May be used alone or also in combinations with other antimicrobial agents in order to fight acne more effectively. Use levels: 0.5-2.0%.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
BODYGLIDE FOR HER

Approved Use

helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns.

Launch Date

2009
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.43 μg/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
30 μg × h/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.69 h
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.
2015-12-01
[Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions].
1994-03
[The effect of aldioxa on the formation of gastritis induced with sodium hydroxide].
1990-11
[Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats].
1989-11
[Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity].
1962-07-01

Sample Use Guides

In general, for adults, take 3 to 4 tablets (300 to 400 mg of the active ingredient) a day, in 3 to 4 divided doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
ALCLOXA
INCI   INN   JAN   MART.   USAN   VANDF   WHO-DD  
INCI   INN   USAN  
Official Name English
ALUMINUM CHLORHYDROXY ALLANTOINATE
II  
Preferred Name English
ALUMINIUM, CHLOROTETRAHYDROXY((4,5-DIHYDRO-2-HYDROXY-5-OXO-1H-IMIDAZOL-4-YL)UREATO)DI-
Common Name English
CHLOROTETRAHYDROXY((2-HYDROXY-5-OXO-2-IMIDAZOLIN-4-YL)UREATO)DIALUMINIUM
Common Name English
Chlorotetrahydroxy[(2-hydroxy-5-oxo-2-imidazolin-4-yl)ureato]dialuminum
Common Name English
ALLANTOLOX
Brand Name English
RC-173
Code English
ALUMINIUM CHLORHYDROXY ALLANTOINATE
Common Name English
ALCLOXA [JAN]
Common Name English
ALCLOXA [MART.]
Common Name English
ALCLOXA [USAN]
Common Name English
Alcloxa [WHO-DD]
Common Name English
ALUMINUM CHLOROHYDROXY ALLANTOINATE
Common Name English
alcloxa [INN]
Common Name English
ALUMINUM CHLORHYDROXY ALLANTOINATE [II]
Common Name English
ALCLOXA [VANDF]
Common Name English
ALUMINUM, CHLOROTETRAHYDROXY((4,5-DIHYDRO-2-HYDROXY-5-OXO-1H-IMIDAZOL-4-YL)UREATO)DI-
Common Name English
ALUMINIUM CHLOROHYDROXY ALLANTOINATE
Common Name English
ALCA
Code English
Classification Tree Code System Code
CFR 21 CFR 346.20
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
NCI_THESAURUS C29700
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
EPA PESTICIDE CODE 85703
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C76518
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
RXCUI
1305554
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY RxNorm
CAS
1317-25-5
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-262-3
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
FDA UNII
18B8O9DQA2
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
SMS_ID
100000087735
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
DRUG BANK
DB11205
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
EVMPD
SUB05301MIG
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
DAILYMED
18B8O9DQA2
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY
INN
1633
Created by admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
PRIMARY